Here are the 10-Q quarterly reports from PTNTD (PTNTD) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow PTNTD and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full PTNTD filings page.
Palatin Technologies reported its quarterly results for the period ended March 31, 2026, showing it is shifting from pure R&D funding toward collaboration-driven revenue. Collaboration and license revenue reached $3.9 million for the quarter and $12.9 million for the nine months, compared with no revenue in the prior-year periods, driven mainly by a $3.75 million non-cash license to Altanispac Labs and earlier payments under its Boehringer Ingelheim retinal disease agreement. Operating expenses remained high, with research and development at $3.5 million and general and administrative at $2.0 million for the quarter. Net loss narrowed to $1.43 million for the quarter and $4.02 million year-to-date. Cash and cash equivalents improved to $10.2 million, supported by multiple 2025 equity and warrant financings totaling tens of millions of dollars, and stockholders’ equity turned positive at $10.6 million. Management still highlights long-term funding needs but believes current cash will fund operations for at least twelve months.
Palatin Technologies reported a larger quarterly loss but a stronger balance sheet in its quarter and six months ended December 31, 2025. Collaboration and license revenue reached $8.96 million for the six-month period, all from a new agreement with Boehringer Ingelheim, compared with no revenue a year earlier.
The company posted a net loss of $7.26 million for the quarter and $2.59 million for six months, narrower than the prior-year six‑month loss. Cash and cash equivalents rose to $14.48 million, up from $2.56 million at June 30, 2025, helped by multiple equity and warrant financings.
Palatin continues to invest heavily in melanocortin receptor programs for obesity and inflammatory diseases while transitioning prior assets to partners. Management expects existing cash to fund operations for at least 12 months after the statements’ issuance but acknowledges the need for substantial additional funding to advance its pipeline.